They inhibit tumor blood vessel formation (angiogenesis) and tumor cell migration (needed for metastasis).
Not exact matches
Trebananib (formally known as AMG 386; Amgen) is a first - in - class peptide - Fc fusion protein (or peptibody) that targets angiogenesis (the growth of new
blood vessels into cancerous
tumors) by
inhibiting the binding of both angiopoietin 1 and 2 to the Tie2 receptor.
«Therapies that
inhibit tumors»
blood vessel development also seem to have considerable merit.
One drug attacks cancer cells; the other
inhibits cancer cell formation and the growth of
blood vessels at
tumor sites.
These proteins, such as endostatin,
inhibit the growth of
blood vessels that the
tumors need to grow and spread (ScienceNOW, 23 January 1997).
This treatment
inhibits the formation of new
blood vessels that can help a
tumor grow.
Earlier studies by Basu and others have shown that dopamine blocks the growth of new
blood vessels in
tumors by
inhibiting the action of vascular endothelial growth factor - A (VEGF - A).
5/7/2007 Targeting Sugar on
Blood Vessels May Inhibit Cancer Growth In a study that could point to novel therapies to prevent cancer spread, or metastasis, researchers at the University of California, San Diego (UCSD) School of Medicine have targeted a sugar that supports blood vessel growth in the t
Blood Vessels May
Inhibit Cancer Growth In a study that could point to novel therapies to prevent cancer spread, or metastasis, researchers at the University of California, San Diego (UCSD) School of Medicine have targeted a sugar that supports
blood vessel growth in the t
blood vessel growth in the
tumor.
They also act aggressively against cancer by preventing cancer cell proliferation, inducing apoptosis — or cancer cell «suicide» — and
inhibiting the formation of new
blood vessels that nourish
tumor growth.
In addition, they detoxify and neutralize carcinogens in the body, while
inhibiting angiogenesis — the cancer - promoting growth of
blood vessels that nourish
tumors.
Disappointingly, the results of these experiments have shown that the most abundant antibody fragment that we isolated from our library does not appear to affect the interaction of VEGF with its receptor suggesting that this clone would not
inhibit the biological effects of VEGF on
tumor blood vessels.